Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could cost it billions if the drug loses its licence.
Roche’s new targeted lung cancer treatment Alecensa has shown itself to be superior to Pfizer’s established rival Xalkori in a head-to-head trial as a first line treatment.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
